# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

> **NCT07136103** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ABBV-277
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07136103
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-19
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136103, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07136103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*